The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! The stock is up 12.70% or $0.4 after the news, hitting $3.55 per share. About 131,720 shares traded hands. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 69.42% since July 27, 2015 and is downtrending. It has underperformed by 65.10% the S&P500. The move comes after 8 months positive chart setup for the $193.11M company. It was reported on Mar, 2 by Barchart.com. We have $6.25 PT which if reached, will make NASDAQ:ABUS worth $146.76M more.
Analysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to reports earnings on March, 10. They expect $-0.39 EPS, down 44.44% or $0.12 from last year’s $-0.27 per share. After $-0.42 actual EPS reported by Arbutus Biopharma Corp for the previous quarter, Wall Street now forecasts -7.14% EPS growth.
Out of 6 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 5 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Arbutus Biopharma was the topic in 5 analyst reports since August 7, 2015 according to StockzIntelligence Inc.
According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
